Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Enters Services Agreement with CRO to Begin Clinical Studies on Dronabinol and CBD Chewing Gums

SAN DIEGO, April 10, 2019 — Medical Marijuana, Inc. (OTC:MJNA), the first-ever publicly traded cannabis company in the United States, announced that its investment company AXIM® Biotechnologies (“AXIM® Biotech” or “AXIM”) (OTCQB:AXIM), a world leader in cannabinoid research and development, has entered into a Services Agreement with contract research organization (“CRO”) QPS Netherlands BV, a global leader in contract research, to begin separate bio comparison studies with its two leading drug candidates, MedChew® with Dronabinol and CanChew® Rx. Both products are chewing gums containing synthetic tetrahydrocannabinol (THC) and cannabidiol (CBD) respectively, and utilize the company’s patented chewing gum delivery mechanism.

“We look forward to continuing our support for AXIM as they conduct these studies and remain optimistic about the company’s positive future results,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “It is very important for us to be able to prove the efficacy and safety of our products and it is great to see that two of AXIM’s developed products will be tested in these upcoming studies.”

The CRO will conduct two open label single dose studies (varying chew duration and concentration) followed by a double-blind, randomized, multiple dose study to test the bioavailability of Dronabinol in MedChew®. MedChew® formulated with Dronabinol is intended for treatment of chemotherapy-induced nausea and vomiting in cancer and AIDS patients. AXIM® intends to register the product on the basis of a 505(b)(2) application.

An open-label, randomized, three-period crossover pharmacokinetic study will be conducted by the CRO on AXIM®‘s CanChew® Rx product. CanChew® Rx is intended to treat symptoms associated with drug-related psychosis.

“Reaching this agreement is an important step in our clinical development program as we work diligently on the many stages of trials to get our products to those suffering from a range of symptoms,” said John Huemoeller, CEO of AXIM® Biotech. “We are proud to work with a well-respected company such as QPS Netherlands that shares our commitment to excellence to bring well-tested and proven drugs to market.”

To learn more about Medical Marijuana, Inc., visit

To learn more about AXIM Biotechnologies, Inc., visit

About Medical Marijuana, Inc.

We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit

To see Medical Marijuana, Inc.’s corporate video, click here.

Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop.

About AXIM® Biotechnologies

AXIM® Biotechnologies, Inc. ( AXIM ) is a world leader in the research and development of cannabinoid-based pharmaceutical products. Along with building a robust intellectual property portfolio, AXIM is focused on clinical development programs that bring more efficacy and/or lower side effects than existing alternatives and require small to medium budgets and timelines to bring to market which presents a high added-value to the pharmaceutical field.

AXIM’s flagship products include MedChew® with Dronabinol, which is planned to undergo a bioequivalence study to fast track through FDA as an alternative to approved Marinol; CanChew® RL, which is planned to undergo clinical trials for treatment of restless leg syndrome; and MedChew Rx®, a combination cannabidiol (CBD)/tetrahydrocannabinol (THC) functional, controlled-release chewing gum that is planned to undergo clinical trials for the treatment of pain and spasticity associated with Multiple Sclerosis (MS). For more information, please visit


This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.


These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.


Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.

Public Relations Contact:

Andrew Hard

Chief Executive Officer

CMW Media

P. 858-264-6600

[email protected]